Percutaneous radiofrequency thermal ablation in the management of lung tumors: presentation of clinical experience on a series of 35 patients
PDF
Cite
Share
Request
Interventional Radiology - Original Article
P: 290-296
December 2009

Percutaneous radiofrequency thermal ablation in the management of lung tumors: presentation of clinical experience on a series of 35 patients

Diagn Interv Radiol 2009;15(4):290-296
1. Departments of Radiology, Sotiria Hospital Athens, Greece
2. Department of Radiology, Red Cross Hospital of Athens, Athens, Greece
3. Departments of Radiology, Alexandra General Hospital Athens, Greece
4. Department of Nuclear Medicine, University Hospital of Ioannina, Athens, Greece
5. Departments of Radiology, Alexandra General Hospital Athens, Greece
6. Department of Pathology, Ippokrateio Hospital, Athens, Greece
7. Departments of Radiology, Red Cross Hospital Athens, Greece
No information available.
No information available
Received Date: 31.03.2008
Accepted Date: 23.10.2008
PDF
Cite
Share
Request

ABSTRACT

PURPOSE

To present our results in a series of 35 patients with malignant pulmonary lesions, who underwent radiofrequency thermal ablation (RFA) during a period of 18 months.

MATERIALS AND METHODS

In our institution, 55 RFA sessions under computed tomography (CT) guidance were performed on 48 pulmonary malignant lesions (23 inoperable primary and 25 metastatic) in 35 patients.

RESULTS

Total necrosis was noted in 19 primary (82.6%) and in 19 metastatic lesions (76%). In four primary (17.4%) and in six metastatic lesions (14%), partial necrosis was achieved, and a second RFA session was performed. The 6-month spiral CT follow-up demonstrated recurrence in seven lesions (14.5%) (four primary and three metastatic), which were treated with an additional RFA session. Two of the patients who underwent the procedure died of disseminated disease after one year, accounting for a 1-year survival rate of 94.2%. Mean survival was 14.48 ± 3.3 months.

CONCLUSION

RFA is an effective method for treating unresectable lung carcinoma and lung metastases.